Core 2: Neuro-Imaging Core (NIC)

核心 2：神经影像核心 (NIC)

• 批准号: 10673771
• 负责人: Benjamin M. Ellingson
• 金额: $ 19.17万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-11 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10673771
• 关键词: Address; Amines; Anatomy; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Archives; BCL2L1 gene; Beds; Biological Markers; Blood Vessels; Blood Volume; Brain; CD8B1 gene; Caliber; Cataloging; Cell Density; Cellularity; Clinic; Clinical; Clinical Trials; Companions; Complex; Computer software; Corpus striatum structure; Data; Diffusion; Diffusion Magnetic Resonance Imaging; Dopamine; EGFR inhibition; Environment; Evaluation; Functional Imaging; Glioblastoma; Glioma; Goals; Growth; Guidelines; Human; Image; Imaging Techniques; Imaging technology; ImmunoPET; Immunotherapy; In Situ; Individual; International; Link; Macrophage; Magnetic Resonance Imaging; Malignant neoplasm of brain; Measurement; Metabolic; Patient imaging; Patients; Perfusion; Phenotype; Physiological; Positron-Emission Tomography; Procedures; Process; Prognosis; Protocols documentation; Public Health; Radiation; Recurrent tumor; Reproduction spores; Research; Research Personnel; Resolution; Resources; Secure; Standardization; T-Lymphocyte; Techniques; Therapeutic; Therapeutic Clinical Trial; Tracer; Translations; Tumor Biology; Tumor-associated macrophages; Vascular Permeabilities; anatomic imaging; brain tissue; brain tumor imaging; clinical imaging; effective therapy; experience; ferumoxytol; fluorodeoxyglucose; fluorodeoxyglucose positron emission tomography; imaging approach; in vivo; indexing; insight; metabolic imaging; molecular imaging; neoplastic cell; neuro-oncology; neuroimaging; novel; novel therapeutic intervention; novel therapeutics; perfusion imaging; pre-clinical; preclinical imaging; presynaptic; radiological imaging; response; subventricular zone; tool; treatment response; tumor; tumor metabolism; tumor microenvironment

PROJECT SUMMARY/ABSTRACT – Neuro-Imaging Core (NIC) The extremely poor prognosis and lack of effective treatments for glioblastoma (GBM) remains a significant public health issue. While traditional MRI techniques are valuable in determining GBM response to common anti-neoplastic therapies, novel treatments including immunotherapies, anti-angiogenic agents, or therapies that alter tumor metabolism may result in radiographic changes that are challenging to differentiate from non- responsive or growing tumor. Therefore, the primary goal of the Neuro-Imaging Core (NIC) will be to provide advanced MRI and PET imaging support with established reliability and consistency to SPORE project investigators for their respective projects. Specifically, the NIC will use quantitative µMRI and µPET for pre- clinical imaging (Aim 1) and state-of-the-art MR and PET imaging acquisition, advanced post-processing, and novel analysis tools for clinical imaging of patients in novel clinical trials (Aim 2). Additionally, we will provide professional expertise and resources for traditional and enhanced radiographic response assessment for the clinical trials for individual SPORE projects (Aim 3). Hence, this Core will add value to the overall SPORE by helping investigators to better understand the in situ metabolic, physiologic, functional, and traditional radiographic changes within the brain and tumor to address specific objectives of each of the UCLA Brain Cancer SPORE projects. Another main goal of the NIC is to understand the link between metabolic and/or physiologic imaging and tumor biology to reliably delineate treatment response versus recurrent tumor, which in turn will facilitate the direct translation of new MR-PET companion biomarkers/techniques to the clinic for the evaluation of treatment response in ongoing and new therapeutic clinical trials resulting from the SPORE projects and cores.

项目摘要/摘要 – 神经影像核心 (NIC) 胶质母细胞瘤（GBM）极差的预后和缺乏有效的治疗方法仍然是一个重要的问题 虽然传统的 MRI 技术对于确定 GBM 对常见问题的反应很有价值。 抗肿瘤疗法、新疗法，包括免疫疗法、抗血管生成剂或疗法 改变肿瘤代谢可能会导致放射学变化，这些变化很难与非肿瘤区分开来。 因此，神经影像核心 (NIC) 的主要目标是提供反应性或生长中的肿瘤。 先进的 MRI 和 PET 成像支持，与 SPORE 项目具有既定的可靠性和一致性 具体来说，NIC 将使用定量 µMRI 和 µPET 进行预检测。 临床成像（目标 1）以及最先进的 MR 和 PET 成像采集、先进的后处理以及 此外，我们将提供用于新型临床试验中患者临床成像的新型分析工具（目标 2）。 用于传统和增强放射学反应评估的专业知识和资源 各个 SPORE 项目的临床试验（目标 3）因此，该核心将为整个 SPORE 增加价值。 帮助研究人员更好地了解原位代谢、生理、功能和传统 大脑和肿瘤内的放射学变化，以实现加州大学洛杉矶分校每个大脑的特定目标 NIC 的另一个主要目标是了解代谢和/或癌症之间的联系。 生理成像和肿瘤生物学能够可靠地描述治疗反应与复发肿瘤的关系， 反过来将有助于将新的 MR-PET 伴随生物标志物/技术直接转化为临床 评估 SPORE 正在进行的和新的治疗临床试验中的治疗反应 项目和核心。